TRexBio Closes $84M Series B to Advance Immune-Based Therapeutics
Slice of Healthcare Team
Nov 15, 2024
Key Highlights
- TRexBio raises $84M in Series B led by Delos Capital with new investors Avego BioScience and Agent Capital.
- Funds to advance TRB-061, a TNFR2 agonist, into clinical trials for autoimmune and inflammatory diseases.
- Pipeline expansion to include new candidate TRB-071, leveraging TRexBio’s unique immune-focused platform.
Source: Business Wire
Notable Quotes
“ Regulatory T cells—and TRexBio’s lead program TRB-061 in particular—offer the potential to unlock a new pillar of therapeutic care for autoimmune and inflammatory diseases. ”
Dr. Eric Huang, Partner at Delos Capital
“ The funding from this Series B financing enables us to enter the clinic early next year with TRB-061, and to start exploring the breadth of potential therapeutic applications for this novel therapy. ”
Johnston Erwin, CEO at TRexBio
